News | December 01, 2023
Biocon Biologics completes Integration of Viatris' Biosimilar business
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Total transaction value of the divestment is Rs. 3,660 million
Preclina is renowned for its highly specialized services in autoimmune and inflammatory disorders
The launch of HULIO in the United States is an important milestone for Biocon Biologics
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
_256_384.jpeg)
Launched Pathology Laboratory in Vijayawada offering a wide range of best-in-class diagnostic services with over 2500+ tests
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
European approval is based on robust Phase III data showing Cosentyx provided rapid symptom relief from as early as Week 4, with response rates continuing to improve up to 1 year1,3-5
Continues to Expand its Presence in South India
Subscribe To Our Newsletter & Stay Updated
